Extended Data Figure 1. Genome-scale activation screen for lncRNA loci involved in BRAF inhibitor resistance.

a, Scatterplots showing lncRNA-targeting and non-targeting sgRNA frequencies after vemurafenib (vemu) or control treatment from n = 4 infection replicates. b, RIGER P values for the top 100 hits from the previous SAM protein-coding gene screen ¹² compared to the SAM lncRNA loci screen. c, For each candidate lncRNA locus, 10 sgRNAs were designed to target the proximal promoter region (800 bp upstream of the TSS). The relationship between the highest sgRNA enrichment in vemurafenib-treated compared to control condition across screening bioreps (n = 4) and respective spacer position suggests that sgRNAs targeting closer to the annotated TSS are not necessarily more effective, consistent with previous results ¹².